- Home
- Publications
- Publication Search
- Publication Details
Title
ACTC1 as an invasion and prognosis marker in glioma
Authors
Keywords
-
Journal
JOURNAL OF NEUROSURGERY
Volume 126, Issue 2, Pages 467-475
Publisher
Journal of Neurosurgery Publishing Group (JNSPG)
Online
2016-04-15
DOI
10.3171/2016.1.jns152075
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Survival Outcomes in Elderly Patients with Glioblastoma
- (2015) D.S. Tsang et al. CLINICAL ONCOLOGY
- Trends and Outcomes in the Treatment of Gliomas Based on Data during 2001–2004 from the Brain Tumor Registry of Japan
- (2015) Yoshitaka NARITA et al. NEUROLOGIA MEDICO-CHIRURGICA
- Decreased miRNA-637 is an unfavorable prognosis marker and promotes glioma cell growth, migration and invasion via direct targeting Akt1
- (2015) T Que et al. ONCOGENE
- Suppressor of fused (Sufu) represses Gli1 transcription and nuclear accumulation, inhibits glioma cell proliferation, invasion and vasculogenic mimicry, improving glioma chemo-sensitivity and prognosis
- (2015) Xing Liu et al. Oncotarget
- International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading
- (2014) David N. Louis et al. BRAIN PATHOLOGY
- Is Supratotal Resection of Glioblastoma in Noneloquent Areas Possible?
- (2014) Hugues Duffau World Neurosurgery
- Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma
- (2013) Kaisorn L. Chaichana et al. NEURO-ONCOLOGY
- High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma
- (2012) Chunzhi Zhang et al. Journal of Translational Medicine
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009
- (2012) T. A. Dolecek et al. NEURO-ONCOLOGY
- AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
- (2011) O. L. Chinot et al. ADVANCES IN THERAPY
- An extent of resection threshold for newly diagnosed glioblastomas
- (2011) Nader Sanai et al. JOURNAL OF NEUROSURGERY
- Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
- (2010) Christian Hartmann et al. ACTA NEUROPATHOLOGICA
- HSP90 modulates actin dynamics: Inhibition of HSP90 leads to decreased cell motility and impairs invasion
- (2010) Aftab Taiyab et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
- (2010) M. J. van den Bent et al. CLINICAL CANCER RESEARCH
- IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
- (2009) S. Nobusawa et al. CLINICAL CANCER RESEARCH
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Actin, a Central Player in Cell Shape and Movement
- (2009) T. D. Pollard et al. SCIENCE
- Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer
- (2008) L. Toschi et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More